Eyenovia (NASDAQ:EYEN) Receives Market Perform Rating from William Blair

Eyenovia (NASDAQ:EYEN)‘s stock had its “market perform” rating restated by William Blair in a research report issued on Friday,Benzinga reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research note on Wednesday.

Eyenovia Trading Down 68.3 %

EYEN stock traded down $0.23 during trading on Friday, hitting $0.11. The company had a trading volume of 38,368,520 shares, compared to its average volume of 1,382,547. The company has a current ratio of 0.74, a quick ratio of 0.27 and a debt-to-equity ratio of 0.58. Eyenovia has a one year low of $0.09 and a one year high of $2.57. The business has a 50-day moving average of $0.50 and a 200-day moving average of $0.71. The stock has a market cap of $6.91 million, a PE ratio of -0.14 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same quarter in the previous year, the firm earned ($0.18) earnings per share. Research analysts predict that Eyenovia will post -0.56 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Michael M. Rowe bought 50,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the completion of the transaction, the chief executive officer now directly owns 82,927 shares in the company, valued at $47,268.39. This trade represents a 151.85 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EYEN. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eyenovia during the second quarter worth about $26,000. Ground Swell Capital LLC purchased a new position in shares of Eyenovia during the 2nd quarter valued at about $27,000. Nations Financial Group Inc. IA ADV boosted its stake in Eyenovia by 24.4% in the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares in the last quarter. Financial Management Network Inc. bought a new position in Eyenovia during the third quarter valued at approximately $39,000. Finally, SkyView Investment Advisors LLC purchased a new position in shares of Eyenovia during the second quarter worth approximately $87,000. 25.84% of the stock is currently owned by hedge funds and other institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.